Priapus Toxin™

Mechanism and Research Priapus Toxin™ applies the same autonomic nervous system mechanism as Clitoxin™ — but to male penile tissue. When Xeomin® is injected into the corpus cavernosum, it is taken up by axonal transport to the ganglia in the pelvic plexus, which signal the arousal center in the hypothalamus, raising the baseline arousal set point. Additionally, botulinum toxin relaxes smooth muscle in penile arterioles, increasing blood flow and engorgement. It also stimulates neovascularization (new blood vessel growth), neurogenesis (new nerve growth), and collagenesis — effects documented in wound-healing research dating to the 1950s. For premature ejaculation specifically: the mechanism is reduction of smooth muscle hyperactivity and penile hypersensitivity that lowers the ejaculatory threshold. Published case series and clinical reports show meaningful improvement in ejaculatory latency in men treated with intracavernosal botulinum toxin. For vascular ED: smooth muscle relaxation increases arterial blood flow to erectile tissue, complementing the regenerative effects of PRP and shockwave therapy. For Peyronie's disease: smooth muscle relaxation in the plaque area may reduce tissue tension and discomfort associated with curvature. Xeomin® (incobotulinumtoxinA) is the only product authorized for this use under our clinical framework — the same product used in the published Runels research. Botulinum toxin has been used millions of times annually in women and men for two decades with a well-established safety record at the dosages used for these procedures.